Cargando…
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies
BACKGROUND: Arginine depletion interferes with pyrimidine metabolism and DNA damage-repair pathways, and pairing arginine deiminase pegylated with 20,000-molecular-weight polyethylene glycol (ADI-PEG20) with platinum enhances cytotoxicity in vitro and in vivo in arginine auxotrophs. METHODS: This si...
Autores principales: | Yao, Shuyang, Janku, Filip, Subbiah, Vivek, Stewart, John, Patel, Sapna Pradyuman, Kaseb, Ahmed, Westin, Shannon Neville, Naing, Aung, Tsimberidou, Apostolia Maria, Hong, David, Piha-Paul, Sarina Anne, Shi, Nai, Johnston, Amanda, Bomalaski, John, Fu, Siqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076217/ https://www.ncbi.nlm.nih.gov/pubmed/33674736 http://dx.doi.org/10.1038/s41416-020-01230-8 |
Ejemplares similares
-
Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
por: Yao, Shuyang, et al.
Publicado: (2021) -
Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2015) -
Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2013) -
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
por: Hou, Ming-Mo, et al.
Publicado: (2016) -
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)